RADNOR, Pa., Jan. 4, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat serious acute-care conditions, announced that it has completed enrollment of 215 patients in its multinational Phase 2 clinical trial designed to evaluate PMX-30063 defensin-mimetic antibiotic in treating patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by Staphylococcus aureus, including methicillin-resistant Staph aureus (MRSA). This is the first clinical efficacy study conducted in patients with this new defensin-mimetic antibiotic class. In December 2011, PolyMedix reported encouraging efficacy and safety data from an interim analysis of this study, and expects to report data from the full study in the first half of 2012.
